Consensus Aquestive Therapeutics, Inc.

Stocks

AQST

US03843E1047

Pharmaceuticals

Market Closed - Nasdaq 23:00:00 29/09/2026 +03			5-day change	1st Jan Change
4.670 ^USD	-1.68%		-5.66%	-27.71%

09-17	Aquestive Therapeutics Resubmits New Drug Application to FDA for Anaphylm (Dibutepinephrine) Sublingual Film	CI
09-17	Aquestive Therapeutics Resubmits Anaphylm NDA to FDA	MT

Evolution of the Average Target: Aquestive Therapeutics, Inc.

Evolution of the Target Price: Aquestive Therapeutics, Inc.

Changes in Analyst Recommendations: Aquestive Therapeutics, Inc.

1ee913c7e72c7.rCli-LF75tCFAkS7-PYk9yjl9VS9Y8HLis7e0hrKeq8.-GgEsdQDh4LrdQ7UnMRTsW63rzfrB5ag2r2BjUibI_r8RlSZwD-3g-1gDQ~83b87fbe39acc45b250128699acec3b8

Analysts' recommendations: Aquestive Therapeutics, Inc.

01-09	Top Midday Decliners	MT
11-04	Aquestive Therapeutics, Inc. Announces Executive Appointments	CI
08/09/25	Oppenheimer Adjusts Aquestive Therapeutics Price Target to $8 From $7, Maintains Outperform Rating	MT
17/12/24	Cantor Fitzgerald Initiates Aquestive Therapeutics at Overweight With $17 Price Target	MT
10/05/24	Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target	MT
11/04/24	Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	MT
28/03/24	Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target	MT
18/03/24	H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating	MT
15/03/24	JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating	MT
11/03/24	HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $7 From $6, Maintains Buy Rating	MT
07/03/24	Wedbush Lifts Aquestive Therapeutics' PT to $9 From $4 After Model Adjustments, Keeps Outperform Rating	MT
08/11/23	HC Wainwright Raises Price Target on Aquestive Therapeutics to $6 From $5, Maintains Buy Rating	MT
10/08/23	Wedbush Lifts Aquestive Therapeutics' Price Target to $4 From $3 Due to Decreased Share Count, Keeps Outperform Rating	MT
03/07/23	Wedbush Trims Aquestive Therapeutics' PT to $3 From $4, Pushes US, EU Launch Estimates for Anaphylm/Anaphylaxis; Keeps Outperform Rating	MT
09/03/23	Wedbush Upgrades Aquestive Therapeutics to Outperform Rating From Neutral, Adjusts Price Target to $4 From $3	MT
31/01/23	Wedbush Downgrades Aquestive Therapeutics to Neutral From Outperform, Notes Limited Cash Runway; Trims Price Target to $3 From $4	MT
04/11/22	Alliance Global Partners Adjusts Price Target on Aquestive Therapeutics to $7 From $10, Maintains Buy Rating	MT
07/09/22	Oppenheimer Initiates Coverage on Aquestive Therapeutics With Outperform Rating, $8.50 Price Target	MT
06/09/22	HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $6, Reiterates Buy Rating	MT
01/09/22	BMO Capital Adjusts Aquestive Therapeutics' Price Target to $6 from $9, Maintains Outperform Rating	MT
30/08/22	Alliance Global Initiates Aquestive Therapeutics at Buy Rating With $10 Price Target	MT
04/08/22	Wedbush Adjusts Price Target on Aquestive Therapeutics to $4 From $8 on Potential Share Count Increase; Outperform Rating Kept	MT
21/06/22	HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $8, Reiterates Buy Rating	MT
31/05/22	HC Wainwright Adjusts Aquestive Therapeutics' Price Target to $8 From $14, Keeps Buy Rating	MT
10/03/22	Wedbush Adjusts Aquestive Therapeutics' Price Target to $8 From $26, Removes Libervant From Pipeline Valuation; Outperform Rating Kept	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AQUESTIVE THERAPEUTICS, INC.					+96.49%
	ELI LILLY AND COMPANY					+12.16%
	JOHNSON & JOHNSON					+2.19%
	ABBVIE INC.					+4.63%
	ROCHE HOLDING AG					+5.61%
	NOVARTIS AG					+4.42%
	ASTRAZENECA PLC					+27.66%
	AMGEN INC.					-6.91%
	GILEAD SCIENCES, INC.					+4.23%
	NOVO NORDISK A/S					+21.93%
	Average					+17.24%
	Weighted average by Cap.					+8.16%